The myriad essential roles of microRNAs in cardiovascular homeostasis and disease

Genes and Diseases

Volumn 1, Issue 1, 2014, Pages 18-39

  Neppl, Ronald L ^a,b   Wang, Da Zhi ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cardiac; Cardiovascular; MicroRNA; MiRNA; Molecular biology; Physiology; RNAi

Indexed keywords

CYTOKINE; GROWTH FACTOR; MICRORNA;

ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CELL COMMUNICATION; CYTOKINE RELEASE; ENDOTHELIUM CELL; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HOMEOSTASIS; HUMAN; HYPERTENSION; LIVER CELL; PANCREAS ISLET BETA CELL; REVIEW; SUBARACHNOID HEMORRHAGE; VASCULAR SMOOTH MUSCLE;

EID: 84937015370     PISSN: None     EISSN: 23523042     Source Type: Journal    
DOI: 10.1016/j.gendis.2014.06.003     Document Type: Review

References (304)

1. Heron M. Deaths: leading causes for 2010. Natl Vital Stat Rep Dec 2013, 62(6):1-97.
2. Yang Q., Cogswell M.E., Flanders W.D., Hong Y., Zhang Z., Loustalot F., et al. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA Mar 28 2012, 307(12):1273-1283.
3. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Blaha M.J., et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation Jan 21 2014, 129(3):e28-e292.
4. Heidenreich P.A., Trogdon J.G., Khavjou O.A., Butler J., Dracup K., Ezekowitz M.D., et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation Mar 1 2011, 123(8):933-944.
5. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature Feb 19 1998, 391(6669):806-811.
6. Tabara H., Sarkissian M., Kelly W.G., Fleenor J., Grishok A., Timmons L., et al. The rde-1 gene, RNA interference, and transposon silencing in C. elegans. Cell Oct 15 1999, 99(2):123-132.
7. Fire A., Albertson D., Harrison S.W., Moerman D.G. Production of antisense RNA leads to effective and specific inhibition of gene expression in C. elegans muscle. Dev Camb Engl Oct 1991, 113(2):503-514.
8. Ambros V. microRNAs: tiny regulators with great potential. Cell Dec 28 2001, 107(7):823-826.
9. Lee R.C., Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Sci New York, N.Y. Oct 26 2001, 294(5543):862-864.
10. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell Dec 3 1993, 75(5):843-854.
11. Giraldez A.J., Cinalli R.M., Glasner M.E., Enright A.J., Thomson J.M., Baskerville S., et al. MicroRNAs regulate brain morphogenesis in zebrafish. Sci New York, N.Y. May 6 2005, 308(5723):833-838.
12. Decembrini S., Bressan D., Vignali R., Pitto L., Mariotti S., Rainaldi G., et al. MicroRNAs couple cell fate and developmental timing in retina. Proc Natl Acad Sci U S A Dec 15 2009, 106(50):21179-21184.
13. Huang Z.P., Chen J.F., Regan J.N., Maguire C.T., Tang R.H., Dong X.R., et al. Loss of microRNAs in neural crest leads to cardiovascular syndromes resembling human congenital heart defects. Arteriosclerosis, Thrombosis, Vasc Biology. Dec 2010, 30(12):2575-2586.
14. Ebert M.S., Sharp P.A. Roles for microRNAs in conferring robustness to biological processes. Cell Apr 27 2012, 149(3):515-524.
15. Cheung T.H., Quach N.L., Charville G.W., Liu L., Park L., Edalati A., et al. Maintenance of muscle stem-cell quiescence by microRNA-489. Nature Feb 23 2012, 482(7386):524-528.
16. Divakaran V., Mann D.L. The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res Nov 7 2008, 103(10):1072-1083.
17. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat Rev Cancer Nov 2006, 6(11):857-866.
18. Mendell J.T., Olson E.N. MicroRNAs in stress signaling and human disease. Cell Mar 16 2012, 148(6):1172-1187.
19. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A Jul 29 2008, 105(30):10513-10518.
20. Lawrie C.H., Gal S., Dunlop H.M., Pushkaran B., Liggins A.P., Pulford K., et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol May 2008, 141(5):672-675.
21. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res Oct 2008, 18(10):997-1006.
22. Ambros V. The functions of animal microRNAs. Nature Sep 16 2004, 431(7006):350-355.
23. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell Jan 23 2004, 116(2):281-297.
24. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell Jan 23 2009, 136(2):215-233.
25. Czech B., Hannon G.J. Small RNA sorting: matchmaking for Argonautes. Nat Rev Genet Jan 2011, 12(1):19-31.
26. Djuranovic S., Nahvi A., Green R. A parsimonious model for gene regulation by miRNAs. Sci New York, N.Y. Feb 4 2011, 331(6017):550-553.
27. Kim V.N. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev May 2005, 6(5):376-385.
28. Rana T.M. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Jan 2007, 8(1):23-36.
29. Garcia-Garcia C., Subirana I., Sala J., Bruguera J., Sanz G., Valle V., et al. Long-term prognosis of first myocardial infarction according to the electrocardiographic pattern (ST elevation myocardial infarction, non-ST elevation myocardial infarction and non-classified myocardial infarction) and revascularization procedures. Am J Cardiol Oct 15 2011, 108(8):1061-1067.
30. Corsten M.F., Dennert R., Jochems S., Kuznetsova T., Devaux Y., Hofstra L., et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet Dec 2010, 3(6):499-506.
31. Wang G.K., Zhu J.Q., Zhang J.T., Li Q., Li Y., He J., et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur heart J Mar 2010, 31(6):659-666.
32. Adachi T., Nakanishi M., Otsuka Y., Nishimura K., Hirokawa G., Goto Y., et al. Plasma microRNA 499 as a biomarker of acute myocardial infarction. Clin Chem Jul 2010, 56(7):1183-1185.
33. D'Alessandra Y., Devanna P., Limana F., Straino S., Di Carlo A., Brambilla P.G., et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur heart J Nov 2010, 31(22):2765-2773.
34. Olivieri F., Antonicelli R., Spazzafumo L., Santini G., Rippo M.R., Galeazzi R., et al. Admission levels of circulating miR-499-5p and risk of death in elderly patients after acute non-ST elevation myocardial infarction. Int J Cardiol Mar 15 2014, 172(2):e276-278.
35. van Rooij E., Quiat D., Johnson B.A., Sutherland L.B., Qi X., Richardson J.A., et al. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell Nov 2009, 17(5):662-673.
36. Steg P.G., Dabbous O.H., Feldman L.J., Cohen-Solal A., Aumont M.C., Lopez-Sendon J., et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation Feb 3 2004, 109(4):494-499.
37. Ezekowitz J.A., Kaul P., Bakal J.A., Armstrong P.W., Welsh R.C., McAlister F.A. Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol Jan 6 2009, 53(1):13-20.
38. Kannel W.B., Sorlie P., McNamara P.M. Prognosis after initial myocardial infarction: the Framingham study. Am J Cardiol Jul 1979, 44(1):53-59.
39. Matsumoto S., Sakata Y., Suna S., Nakatani D., Usami M., Hara M., et al. Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circ Res Jul 19 2013, 113(3):322-326.
40. Matsumoto S., Sakata Y., Nakatani D., Suna S., Mizuno H., Shimizu M., et al. A subset of circulating microRNAs are predictive for cardiac death after discharge for acute myocardial infarction. Biochem biophysical Res Commun Oct 19 2012, 427(2):280-284.
41. Kardasinski M., Thum T. Cardiac fibroblasts on the fast track-scleraxis: from Achilles' heel to anti-fibrotic therapy. J Mol Cell Cardiol Aug 2009, 47(2):174-176.
42. Bosman F.T., Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol Jul 2003, 200(4):423-428.
43. Tomasek J.J., Gabbiani G., Hinz B., Chaponnier C., Brown R.A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol May 2002, 3(5):349-363.
44. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev Jan 1999, 79(1):215-262.
45. Braunwald E. Heart failure. JACC Heart Fail Feb 2013, 1(1):1-20.
46. Jugdutt B.I. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?. Circulation Sep 16 2003, 108(11):1395-1403.
47. Thambo J.B., Bordachar P., Garrigue S., Lafitte S., Sanders P., Reuter S., et al. Detrimental ventricular remodeling in patients with congenital complete heart block and chronic right ventricular apical pacing. Circulation Dec 21 2004, 110(25):3766-3772.
48. Haddad F., Hunt S.A., Rosenthal D.N., Murphy D.J. Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation Mar 18 2008, 117(11):1436-1448.
49. Zornoff L.A., Skali H., Pfeffer M.A., St John Sutton M., Rouleau J.L., Lamas G.A., et al. Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J Am Coll Cardiol May 1 2002, 39(9):1450-1455.
50. da Costa Martins P.A., Bourajjaj M., Gladka M., Kortland M., van Oort R.J., Pinto Y.M., et al. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation Oct 7 2008, 118(15):1567-1576.
51. Kato M., Zhang J., Wang M., Lanting L., Yuan H., Rossi J.J., et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A Feb 27 2007, 104(9):3432-3437.
52. Bernardo B.C., Gao X.M., Winbanks C.E., Boey E.J., Tham Y.K., Kiriazis H., et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci U S A Oct 23 2012, 109(43):17615-17620.
53. Boon R.A., Iekushi K., Lechner S., Seeger T., Fischer A., Heydt S., et al. MicroRNA-34a regulates cardiac ageing and function. Nature Mar 7 2013, 495(7439):107-110.
54. Duisters R.F., Tijsen A.J., Schroen B., Leenders J.J., Lentink V., van der Made I., et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res Jan 30 2009, 104(2):170-178. 176pp. following 178.
55. Matkovich S.J., Wang W., Tu Y., Eschenbacher W.H., Dorn L.E., Condorelli G., et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res Jan 8 2010, 106(1):166-175.
56. van Rooij E., Sutherland L.B., Thatcher J.E., DiMaio J.M., Naseem R.H., Marshall W.S., et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A Sep 2 2008, 105(35):13027-13032.
57. Dawson K., Wakili R., Ordog B., Clauss S., Chen Y., Iwasaki Y., et al. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circ Apr 9 2013, 127(14):1466-1475. 1475e1461-1428.
58. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature Dec 18 2008, 456(7224):980-984.
59. Bronnum H., Andersen D.C., Schneider M., Sandberg M.B., Eskildsen T., Nielsen S.B., et al. miR-21 promotes fibrogenic epithelial-to-mesenchymal transition of epicardial mesothelial cells involving Programmed Cell Death 4 and Sprouty-1. PLoS One 2013, 8(2):e56280.
60. Zhang Z., Zha Y., Hu W., Huang Z., Gao Z., Zang Y., et al. The autoregulatory feedback loop of microRNA-21/programmed cell death protein 4/activation protein-1 (MiR-21/PDCD4/AP-1) as a driving force for hepatic fibrosis development. J Biol Chem Dec 27 2013, 288(52):37082-37093.
61. Roy S., Khanna S., Hussain S.R., Biswas S., Azad A., Rink C., et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res Apr 1 2009, 82(1):21-29.
62. Kato M., Putta S., Wang M., Yuan H., Lanting L., Nair I., et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol Jul 2009, 11(7):881-889.
63. Kumarswamy R., Volkmann I., Jazbutyte V., Dangwal S., Park D.H., Thum T. Transforming growth factor-beta-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21. Arteriosc Thromb Vasc biology. Feb 2012, 32(2):361-369.
64. Chau B.N., Xin C., Hartner J., Ren S., Castano A.P., Linn G., et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med Feb 15 2012, 4(121):121ra118.
65. Bang C., Batkai S., Dangwal S., Gupta S.K., Foinquinos A., Holzmann A., et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest Apr 17 2014, 124(5):2136-2146.
66. Patrick D.M., Montgomery R.L., Qi X., Obad S., Kauppinen S., Hill J.A., et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest Nov 2010, 120(11):3912-3916.
67. van Rooij E., Sutherland L.B., Qi X., Richardson J.A., Hill J., Olson E.N. Control of stress-dependent cardiac growth and gene expression by a microRNA. Sci New York, N.Y. Apr 27 2007, 316(5824):575-579.
68. Callis T.E., Pandya K., Seok H.Y., Tang R.H., Tatsuguchi M., Huang Z.P., et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest Sep 2009, 119(9):2772-2786.
69. Montgomery R.L., Hullinger T.G., Semus H.M., Dickinson B.A., Seto A.G., Lynch J.M., et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation Oct 4 2011, 124(14):1537-1547.
70. Matkovich S.J., Hu Y., Eschenbacher W.H., Dorn L.E., Dorn G.W. Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy. Circ Res Aug 17 2012, 111(5):521-531.
71. D'Angelo D.D., Sakata Y., Lorenz J.N., Boivin G.P., Walsh R.A., Liggett S.B., et al. Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A Jul 22 1997, 94(15):8121-8126.
72. Adams J.W., Sakata Y., Davis M.G., Sah V.P., Wang Y., Liggett S.B., et al. Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci U S A Aug 18 1998, 95(17):10140-10145.
73. Bell M.L., Buvoli M., Leinwand L.A. Uncoupling of expression of an intronic microRNA and its myosin host gene by exon skipping. Mol Cell Biol Apr 2010, 30(8):1937-1945.
74. Wang J.X., Jiao J.Q., Li Q., Long B., Wang K., Liu J.P., et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med Jan 2011, 17(1):71-78.
75. Kolwicz S.C., Purohit S., Tian R. Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res Aug 16 2013, 113(5):603-616.
76. Razeghi P., Young M.E., Alcorn J.L., Moravec C.S., Frazier O.H., Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation Dec 11 2001, 104(24):2923-2931.
77. Wang K., Long B., Jiao J.Q., Wang J.X., Liu J.P., Li Q., et al. miR-484 regulates mitochondrial network through targeting Fis1. Nat Commun 2012, 3:781.
78. Swarbrick A., Woods S.L., Shaw A., Balakrishnan A., Phua Y., Nguyen A., et al. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med Oct 2010, 16(10):1134-1140.
79. el Azzouzi H., Leptidis S., Dirkx E., Hoeks J., van Bree B., Brand K., et al. The hypoxia-inducible microRNA cluster miR-199a approximately 214 targets myocardial PPARdelta and impairs mitochondrial fatty acid oxidation. Cell metab Sep 3 2013, 18(3):341-354.
80. Aurora A.B., Mahmoud A.I., Luo X., Johnson B.A., van Rooij E., Matsuzaki S., et al. MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca(2)(+) overload and cell death. J Clin Invest Apr 2 2012, 122(4):1222-1232.
81. Yang B., Lin H., Xiao J., Lu Y., Luo X., Li B., et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med Apr 2007, 13(4):486-491.
82. Terentyev D., Belevych A.E., Terentyeva R., Martin M.M., Malana G.E., Kuhn D.E., et al. miR-1 overexpression enhances Ca2+ release and promotes cardiac Arrhythmogenesis by targeting PP2A regulatory subunit B56{alpha} and Causing CaMKII-dependent Hyperphosphorylation of RyR2. Circ Res Jan 8 2009, 104(4):514-521.
83. Wahlquist C., Jeong D., Rojas-Munoz A., Kho C., Lee A., Mitsuyama S., et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature Apr 24 2014, 508(7497):531-535.
84. Lu Y., Zhang Y., Wang N., Pan Z., Gao X., Zhang F., et al. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation Dec 7 2010, 122(23):2378-2387.
85. Nattel S. New ideas about atrial fibrillation 50 years on. Nature Jan 10 2002, 415(6868):219-226.
86. Nattel S., Maguy A., Le Bouter S., Yeh Y.H. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev Apr 2007, 87(2):425-456.
87. Van Wagoner D.R., Pond A.L., Lamorgese M., Rossie S.S., McCarthy P.M., Nerbonne J.M. Atrial L-type Ca2+ currents and human atrial fibrillation. Circ Res Sep 3 1999, 85(5):428-436.
88. Chou C.C., Nihei M., Zhou S., Tan A., Kawase A., Macias E.S., et al. Intracellular calcium dynamics and anisotropic reentry in isolated canine pulmonary veins and left atrium. Circulation Jun 7 2005, 111(22):2889-2897.
89. Sayed D., Hong C., Chen I.Y., Lypowy J., Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res Feb 16 2007, 100(3):416-424.
90. Luo X., Pan Z., Shan H., Xiao J., Sun X., Wang N., et al. MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J Clin Invest May 1 2013, 123(5):1939-1951.
91. Heineke J., Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol Aug 2006, 7(8):589-600.
92. Vega R.B., Bassel-Duby R., Olson E.N. Control of cardiac growth and function by calcineurin signaling. J Biol Chem Sep 26 2003, 278(39):36981-36984.
93. da Costa Martins P.A., Salic K., Gladka M.M., Armand A.S., Leptidis S., el Azzouzi H., et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol Dec 2010, 12(12):1220-1227.
94. Dirkx E., Gladka M.M., Philippen L.E., Armand A.S., Kinet V., Leptidis S., et al. Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure. Nat Cell Biol Nov 2013, 15(11):1282-1293.
95. Lin Z., Murtaza I., Wang K., Jiao J., Gao J., Li P.F. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc Natl Acad Sci U S A Jul 21 2009, 106(29):12103-12108.
96. Seok H.Y., Chen J., Kataoka M., Huang Z.P., Ding J., Yan J., et al. Loss of microRNA-155 protects the heart from pathological cardiac hypertrophy. Circ Res Mar 21 2014, 114(10):1585-1595.
97. Pasini D., Cloos P.A., Walfridsson J., Olsson L., Bukowski J.P., Johansen J.V., et al. JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells. Nature Mar 11 2010, 464(7286):306-310.
98. Peng J.C., Valouev A., Swigut T., Zhang J., Zhao Y., Sidow A., et al. Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell Dec 24 2009, 139(7):1290-1302.
99. Heymans S., Corsten M.F., Verhesen W., Carai P., van Leeuwen R.E., Custers K., et al. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation Sep 24 2013, 128(13):1420-1432.
100. Rodriguez A., Vigorito E., Clare S., Warren M.V., Couttet P., Soond D.R., et al. Requirement of bic/microRNA-155 for normal immune function. Sci New York, N.Y Apr 27 2007, 316(5824):608-611.
101. Thai T.H., Calado D.P., Casola S., Ansel K.M., Xiao C., Xue Y., et al. Regulation of the germinal center response by microRNA-155. Sci New York, N.Y. Apr 27 2007, 316(5824):604-608.
102. Ucar A., Gupta S.K., Fiedler J., Erikci E., Kardasinski M., Batkai S., et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun 2012, 3:1078.
103. Sandri M., Sandri C., Gilbert A., Skurk C., Calabria E., Picard A., et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell Apr 30 2004, 117(3):399-412.
104. Li H.H., Kedar V., Zhang C., McDonough H., Arya R., Wang D.Z., et al. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest Oct 2004, 114(8):1058-1071.
105. Chen J.F., Mandel E.M., Thomson J.M., Wu Q., Callis T.E., Hammond S.M., et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet Feb 2006, 38(2):228-233.
106. Care A., Catalucci D., Felicetti F., Bonci D., Addario A., Gallo P., et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med May 2007, 13(5):613-618.
107. Karakikes I., Chaanine A.H., Kang S., Mukete B.N., Jeong D., Zhang S., et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc Apr 2013, 2(2):e000078.
108. Brown J.H., Del Re D.P., Sussman M.A. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res Mar 31 2006, 98(6):730-742.
109. Nagai T., Tanaka-Ishikawa M., Aikawa R., Ishihara H., Zhu W., Yazaki Y., et al. Cdc42 plays a critical role in assembly of sarcomere units in series of cardiac myocytes. Biochem Biophys Res Commun Jun 13 2003, 305(4):806-810.
110. Owens G.K., Kumar M.S., Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev Jul 2004, 84(3):767-801.
111. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature Apr 29 1993, 362(6423):801-809.
112. Berliner J.A., Navab M., Fogelman A.M., Frank J.S., Demer L.L., Edwards P.A., et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation May 1 1995, 91(9):2488-2496.
113. Berliner J.A., Watson A.D. A role for oxidized phospholipids in atherosclerosis. N. Engl J Med Jul 7 2005, 353(1):9-11.
114. Kannel W.B., Castelli W.P., Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med Jan 1979, 90(1):85-91.
115. Libby P. Inflammation in atherosclerosis. Nature Dec 19-26 2002, 420(6917):868-874.
116. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circ 2002, 105(9):1135-1143.
117. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl J Med 2005, 352(16):1685-1695.
118. Kovanen P.T., Kaartinen M., Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circ Sep 1995, 92(5):1084-1088.
119. Hansson G.K., Holm J., Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989, 135(1):169-175.
120. van der Wal A.C., Becker A.E., van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994, 89(1):36-44.
121. Cybulsky M.I., Iiyama K., Li H., Zhu S., Chen M., Iiyama M., et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001, 107(10):1255-1262.
122. Fang Y., Shi C., Manduchi E., Civelek M., Davies P.F. MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc Natl Acad Sci U S A 2010, 107(30):13450-13455.
123. Zhou J., Wang K.C., Wu W., Subramaniam S., Shyy J.Y., Chiu J.J., et al. MicroRNA-21 targets peroxisome proliferators-activated receptor-alpha in an autoregulatory loop to modulate flow-induced endothelial inflammation. Proc Natl Acad Sci U S A 2011, 108(25):10355-10360.
124. Wu W., Xiao H., Laguna-Fernandez A., Villarreal G., Wang K.C., Geary G.G., et al. Flow-Dependent regulation of Kruppel-like factor 2 is mediated by MicroRNA-92a. Circulation 2011, 124(5):633-641.
125. Wang K.C., Garmire L.X., Young A., Nguyen P., Trinh A., Subramaniam S., et al. Role of microRNA-23b in flow-regulation of Rb phosphorylation and endothelial cell growth. Proc Natl Acad Sci U S A 2010, 107(7):3234-3239.
126. Hergenreider E., Heydt S., Treguer K., Boettger T., Horrevoets A.J., Zeiher A.M., et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol 2012, 14(3):249-256.
127. Boettger T., Beetz N., Kostin S., Schneider J., Kruger M., Hein L., et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest 2009, 119(9):2634-2647.
128. Xin M., Small E.M., Sutherland L.B., Qi X., McAnally J., Plato C.F., et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes & development 2009, 23(18):2166-2178.
129. Cheng Y., Liu X., Yang J., Lin Y., Xu D.Z., Lu Q., et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res 2009, 105(2):158-166.
130. Zernecke A., Bidzhekov K., Noels H., Shagdarsuren E., Gan L., Denecke B., et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009, 2(100):ra81.
131. Damas J.K., Waehre T., Yndestad A., Ueland T., Muller F., Eiken H.G., et al. Stromal cell-derived factor-1alpha in unstable angina: potential antiinflammatory and matrix-stabilizing effects. Circulation 2002, 106(1):36-42.
132. Seeger F.H., Rasper T., Koyanagi M., Fox H., Zeiher A.M., Dimmeler S. CXCR4 expression determines functional activity of bone marrow-derived mononuclear cells for therapeutic neovascularization in acute ischemia. Arteriosc Thromb Vasc Biol 2009, 29(11):1802-1809.
133. Fish J.E., Santoro M.M., Morton S.U., Yu S., Yeh R.F., Wythe J.D., et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008, 15(2):272-284.
134. Wang S., Aurora A.B., Johnson B.A., Qi X., McAnally J., Hill J.A., et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008, 15(2):261-271.
135. Zhou J., Li Y.S., Nguyen P., Wang K.C., Weiss A., Kuo Y.C., et al. Regulation of vascular smooth muscle cell turnover by endothelial cell-secreted microRNA-126: role of shear stress. Circ Res 2013, 113(1):40-51.
136. Katare R., Riu F., Mitchell K., Gubernator M., Campagnolo P., Cui Y., et al. Transplantation of human pericyte progenitor cells improves the repair of infarcted heart through activation of an angiogenic program involving micro-RNA-132. Circ Res 2011, 109(8):894-906.
137. Klein M.E., Lioy D.T., Ma L., Impey S., Mandel G., Goodman R.H. Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nat Neurosci 2007, 10(12):1513-1514.
138. Lagos D., Pollara G., Henderson S., Gratrix F., Fabani M., Milne R.S., et al. miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator. Nat Cell Biol 2010, 12(5):513-519.
139. Anand S., Majeti B.K., Acevedo L.M., Murphy E.A., Mukthavaram R., Scheppke L., et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med 2010, 16(8):909-914.
140. Westenskow P.D., Kurihara T., Aguilar E., Scheppke E.L., Moreno S.K., Wittgrove C., et al. Ras pathway inhibition prevents neovascularization by repressing endothelial cell sprouting. J Clin Invest 2013, 123(11):4900-4908.
141. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Sci New York, N.Y 1997, 277(5322):55-60.
142. Fiedler U., Reiss Y., Scharpfenecker M., Grunow V., Koidl S., Thurston G., et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006, 12(2):235-239.
143. Gale N.W., Thurston G., Hackett S.F., Renard R., Wang Q., McClain J., et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002, 3(3):411-423.
144. Nagy J.A., Dvorak A.M., Dvorak H.F. Vascular hyperpermeability, angiogenesis, and stroma generation. Cold Spring Harb Perspect Med 2012, 2(2):a006544.
145. Senger D.R., Van de Water L., Brown L.F., Nagy J.A., Yeo K.T., Yeo T.K., et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993, 12(3-4):303-324.
146. Lee C.G., Link H., Baluk P., Homer R.J., Chapoval S., Bhandari V., et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 2004, 10(10):1095-1103.
147. Cursiefen C., Chen L., Borges L.P., Jackson D., Cao J., Radziejewski C., et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004, 113(7):1040-1050.
148. Kim I., Moon S.O., Park S.K., Chae S.W., Koh G.Y. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res 2001, 89(6):477-479.
149. Yin K.J., Olsen K., Hamblin M., Zhang J., Schwendeman S.P., Chen Y.E. Vascular endothelial cell-specific microRNA-15a inhibits angiogenesis in hindlimb ischemia. J Biol Chem 2012, 287(32):27055-27064.
150. Lei Z., Li B., Yang Z., Fang H., Zhang G.M., Feng Z.H., et al. Regulation of HIF-1alpha and VEGF by miR-20b tunes tumor cells to adapt to the alteration of oxygen concentration. PLoS One 2009, 4(10):e7629.
151. Stahlhut C., Suarez Y., Lu J., Mishima Y., Giraldez A.J. miR-1 and miR-206 regulate angiogenesis by modulating VegfA expression in zebrafish. Dev Camb Engl 2012, 139(23):4356-4364.
152. McArthur K., Feng B., Wu Y., Chen S., Chakrabarti S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes 2011, 60(4):1314-1323.
153. Long J., Wang Y., Wang W., Chang B.H., Danesh F.R. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J Biol Chem 2010, 285(30):23457-23465.
154. Hassel D., Cheng P., White M.P., Ivey K.N., Kroll J., Augustin H.G., et al. MicroRNA-10 regulates the angiogenic behavior of zebrafish and human endothelial cells by promoting vascular endothelial growth factor signaling. Circ Res 2012, 111(11):1421-1433.
155. Zhuang G., Wu X., Jiang Z., Kasman I., Yao J., Guan Y., et al. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J 2012, 31(17):3513-3523.
156. Wurdinger T., Tannous B.A., Saydam O., Skog J., Grau S., Soutschek J., et al. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell 2008, 14(5):382-393.
157. Kuhnert F., Mancuso M.R., Hampton J., Stankunas K., Asano T., Chen C.Z., et al. Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Dev Camb Engl 2008, 135(24):3989-3993.
158. Small E.M., O'Rourke J.R., Moresi V., Sutherland L.B., McAnally J., Gerard R.D., et al. Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486. Proc Natl Acad Sci U S A 2010, 107(9):4218-4223.
159. Agudo J., Ruzo A., Tung N., Salmon H., Leboeuf M., Hashimoto D., et al. The miR-126-VEGFR2 axis controls the innate response to pathogen-associated nucleic acids. Nat Immunol 2014, 15(1):54-62.
160. Nazari-Jahantigh M., Wei Y., Noels H., Akhtar S., Zhou Z., Koenen R.R., et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest 2012, 122(11):4190-4202.
161. Wei Y., Nazari-Jahantigh M., Chan L., Zhu M., Heyll K., Corbalan-Campos J., et al. The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis. Circulation 2013, 127(15):1609-1619.
162. Taganov K.D., Boldin M.P., Chang K.J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 2006, 103(33):12481-12486.
163. Xu X.H., Shah P.K., Faure E., Equils O., Thomas L., Fishbein M.C., et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001, 104(25):3103-3108.
164. Sheedy F.J., Palsson-McDermott E., Hennessy E.J., Martin C., O'Leary J.J., Ruan Q., et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010, 11(2):141-147.
165. Asangani I.A., Rasheed S.A., Nikolova D.A., Leupold J.H., Colburn N.H., Post S., et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27(15):2128-2136.
166. Frankel L.B., Christoffersen N.R., Jacobsen A., Lindow M., Krogh A., Lund A.H. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. The Journal of biological chemistry 2008, 283(2):1026-1033.
167. Ji R., Cheng Y., Yue J., Yang J., Liu X., Chen H., et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res 2007, 100(11):1579-1588.
168. Liu X., Cheng Y., Zhang S., Lin Y., Yang J., Zhang C. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res 2009, 104(4):476-487.
169. Du Y., Gao C., Liu Z., Wang L., Liu B., He F., et al. Upregulation of a disintegrin and metalloproteinase with thrombospondin motifs-7 by miR-29 repression mediates vascular smooth muscle calcification. Arteriosc Thromb Vasc Biol 2012, 32(11):2580-2588.
170. Reilly M.P., Li M., He J., Ferguson J.F., Stylianou I.M., Mehta N.N., et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 2011, 377(9763):383-392.
171. van Setten J., Isgum I., Smolonska J., Ripke S., de Jong P.A., Oudkerk M., et al. Genome-wide association study of coronary and aortic calcification implicates risk loci for coronary artery disease and myocardial infarction. Atherosclerosis 2013, 228(2):400-405.
172. Wang L., Zheng J., Bai X., Liu B., Liu C.J., Xu Q., et al. ADAMTS-7 mediates vascular smooth muscle cell migration and neointima formation in balloon-injured rat arteries. Circ Res 2009, 104(5):688-698.
173. Rong J.X., Li J., Reis E.D., Choudhury R.P., Dansky H.M., Elmalem V.I., et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 2001, 104(20):2447-2452.
174. Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290(17):2292-2300.
175. Vickers K.C., Palmisano B.T., Shoucri B.M., Shamburek R.D., Remaley A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011, 13(4):423-433.
176. Tabet F., Vickers K.C., Cuesta Torres L.F., Wiese C.B., Shoucri B.M., Lambert G., et al. HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nat Commun 2014, 5:3292.
177. Chen C.Z., Li L., Lodish H.F., Bartel D.P. MicroRNAs modulate hematopoietic lineage differentiation. Sci New York, N.Y. 2004, 303(5654):83-86.
178. Rayner K.J., Sheedy F.J., Esau C.C., Hussain F.N., Temel R.E., Parathath S., et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011, 121(7):2921-2931.
179. Rayner K.J., Suarez Y., Davalos A., Parathath S., Fitzgerald M.L., Tamehiro N., et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Sci New York, N.Y. 2010, 328(5985):1570-1573.
180. Rayner K.J., Esau C.C., Hussain F.N., McDaniel A.L., Marshall S.M., van Gils J.M., et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011, 478(7369):404-407.
181. Ramirez C.M., Rotllan N., Vlassov A.V., Davalos A., Li M., Goedeke L., et al. Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144. Circ Res 2013, 112(12):1592-1601.
182. Soh J., Iqbal J., Queiroz J., Fernandez-Hernando C., Hussain M.M. MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat Med 2013, 19(7):892-900.
183. Davalos A., Goedeke L., Smibert P., Ramirez C.M., Warrier N.P., Andreo U., et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A 2011, 108(22):9232-9237.
184. Esau C., Davis S., Murray S.F., Yu X.X., Pandey S.K., Pear M., et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006, 3(2):87-98.
185. Hsu S.H., Wang B., Kota J., Yu J., Costinean S., Kutay H., et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 2012, 122(8):2871-2883.
186. Tsai W.C., Hsu S.D., Hsu C.S., Lai T.C., Chen S.J., Shen R., et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012, 122(8):2884-2897.
187. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. Seventh report of the Joint National Committee on Prevention, detection, Evaluation, and treatment of high blood pressure. Hypertension 2003, 42(6):1206-1252.
188. Guyton A.C. Blood pressure control-special role of the kidneys and body fluids. Sci New York, N.Y. 1991, 252(5014):1813-1816.
189. Lifton R.P., Gharavi A.G., Geller D.S. Molecular mechanisms of human hypertension. Cell 2001, 104(4):545-556.
190. Huang P.L., Huang Z., Mashimo H., Bloch K.D., Moskowitz M.A., Bevan J.A., et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995, 377(6546):239-242.
191. Tang K.M., Wang G.R., Lu P., Karas R.H., Aronovitz M., Heximer S.P., et al. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med 2003, 9(12):1506-1512.
192. Brenner R., Perez G.J., Bonev A.D., Eckman D.M., Kosek J.C., Wiler S.W., et al. Vasoregulation by the beta1 subunit of the calcium-activated potassium channel. Nature 2000, 407(6806):870-876.
193. Zhu Y., Bian Z., Lu P., Karas R.H., Bao L., Cox D., et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Sci New York, N.Y. 2002, 295(5554):505-508.
194. Michael S.K., Surks H.K., Wang Y., Zhu Y., Blanton R., Jamnongjit M., et al. High blood pressure arising from a defect in vascular function. Proc Natl Acad Sci U S A 2008, 105(18):6702-6707.
195. Mehta P.K., Griendling K.K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol 2007, 292(1):C82-C97.
196. Tuder R.M., Marecki J.C., Richter A., Fijalkowska I., Flores S. Pathology of pulmonary hypertension. Clin Chest Med 2007, 28(1):23-42.
197. Schermuly R.T., Ghofrani H.A., Wilkins M.R., Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011, 8(8):443-455.
198. Goel S., Duda D.G., Xu L., Munn L.L., Boucher Y., Fukumura D., et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011, 91(3):1071-1121.
199. Aird W.C. Endothelial cell heterogeneity. Cold Spring Harb Perspect Med 2012, 2(1):a006429.
200. Schober A. Chemokines in vascular dysfunction and remodeling. Arteriosc Thromb Vasc biology. 2008, 28(11):1950-1959.
201. Heeneman S., Sluimer J.C., Daemen M.J. Angiotensin-converting enzyme and vascular remodeling. Circ Res 2007, 101(5):441-454.
202. Eddahibi S., Guignabert C., Barlier-Mur A.M., Dewachter L., Fadel E., Dartevelle P., et al. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 2006, 113(15):1857-1864.
203. Izikki M., Guignabert C., Fadel E., Humbert M., Tu L., Zadigue P., et al. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 2009, 119(3):512-523.
204. Hassoun P.M., Mouthon L., Barbera J.A., Eddahibi S., Flores S.C., Grimminger F., et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009, 54(1 Suppl):S10-S19.
205. Sheikh A.Y., Chun H.J., Glassford A.J., Kundu R.K., Kutschka I., Ardigo D., et al. In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. Am J Physiol Heart Circ Physiol 2008, 294(1):H88-H98.
206. Ishida J., Hashimoto T., Hashimoto Y., Nishiwaki S., Iguchi T., Harada S., et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 2004, 279(25):26274-26279.
207. Zhong J.C., Yu X.Y., Huang Y., Yung L.M., Lau C.W., Lin S.G. Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovasc Res 2007, 74(3):388-395.
208. Chandra S.M., Razavi H., Kim J., Agrawal R., Kundu R.K., de Jesus Perez V., et al. Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arteriosc Thromb Vasc Biol 2011, 31(4):814-820.
209. Alastalo T.P., Li M., Perez Vde J., Pham D., Sawada H., Wang J.K., et al. Disruption of PPARgamma/beta-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest 2011, 121(9):3735-3746.
210. Kim J., Kang Y., Kojima Y., Lighthouse J.K., Hu X., Aldred M.A., et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med 2013, 19(1):74-82.
211. Sun H.X., Zeng D.Y., Li R.T., Pang R.P., Yang H., Hu Y.L., et al. Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension 2012, 60(6):1407-1414.
212. Crowley S.D., Gurley S.B., Herrera M.J., Ruiz P., Griffiths R., Kumar A.P., et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A 2006, 103(47):17985-17990.
213. Spiering W., Kroon A.A., Fuss-Lejeune M.M., Daemen M.J., de Leeuw P.W. Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A(1166)C polymorphism in essential hypertensives on a high sodium diet. Hypertension 2000, 36(3):411-416.
214. van Geel P.P., Pinto Y.M., Voors A.A., Buikema H., Oosterga M., Crijns H.J., et al. Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension 2000, 35(3):717-721.
215. Yang Z., Venardos K., Jones E., Morris B.J., Chin-Dusting J., Kaye D.M. Identification of a novel polymorphism in the 3'UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction. Circulation 2007, 115(10):1269-1274.
216. Chang J., Nicolas E., Marks D., Sander C., Lerro A., Buendia M.A., et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004, 1(2):106-113.
217. Bhattacharyya S.N., Habermacher R., Martine U., Closs E.I., Filipowicz W. Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell 2006, 125(6):1111-1124.
218. Wei Z., Biswas N., Wang L., Courel M., Zhang K., Soler-Jover A., et al. A common genetic variant in the 3'-UTR of vacuolar H+-ATPase ATP6V0A1 creates a micro-RNA motif to alter chromogranin A processing and hypertension risk. Circ Cardiovasc Genet 2011, 4(4):381-389.
219. Mahata S.K., O'Connor D.T., Mahata M., Yoo S.H., Taupenot L., Wu H., et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997, 100(6):1623-1633.
220. Taupenot L., Harper K.L., O'Connor D.T. The chromogranin-secretogranin family. N. Engl J Med 2003, 348(12):1134-1149.
221. O'Connor D.T., Zhu G., Rao F., Taupenot L., Fung M.M., Das M., et al. Heritability and genome-wide linkage in US and australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure. Circulation 2008, 118(3):247-257.
222. Arora P., Wu C., Khan A.M., Bloch D.B., Davis-Dusenbery B.N., Ghorbani A., et al. Atrial natriuretic peptide is negatively regulated by microRNA-425. J Clin Invest 2013, 123(8):3378-3382.
223. Nossent A.Y., Hansen J.L., Doggen C., Quax P.H., Sheikh S.P., Rosendaal F.R. SNPs in microRNA binding sites in 3'-UTRs of RAAS genes influence arterial blood pressure and risk of myocardial infarction. Am J Hypertens 2011, 24(9):999-1006.
224. Ellis E.F., Oelz O., Roberts L.J., Payne N.A., Sweetman B.J., Nies A.S., et al. Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A2. Sci New York, N.Y. 1976, 193(4258):1135-1137.
225. Buzzard C.J., Pfister S.L., Campbell W.B. Endothelium-dependent contractions in rabbit pulmonary artery are mediated by thromboxane A2. Circ Res 1993, 72(5):1023-1034.
226. Neppl R.L., Lubomirov L.T., Momotani K., Pfitzer G., Eto M., Somlyo A.V. Thromboxane A2-induced Bi-directional regulation of cerebral arterial tone. J Biol Chem 2009, 284(10):6348-6360.
227. Semenza G.L. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001, 107(1):1-3.
228. Ghosh G., Subramanian I.V., Adhikari N., Zhang X., Joshi H.P., Basi D., et al. Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-alpha isoforms and promotes angiogenesis. J Clin Invest 2010, 120(11):4141-4154.
229. Kulshreshtha R., Ferracin M., Wojcik S.E., Garzon R., Alder H., Agosto-Perez F.J., et al. A microRNA signature of hypoxia. Mol Cell Biol 2007, 27(5):1859-1867.
230. Kelly T.J., Souza A.L., Clish C.B., Puigserver P. A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1alpha stability through miR-210 suppression of glycerol-3-phosphate dehydrogenase 1-like. Mol Cell Biol 2011, 31(13):2696-2706.
231. Fasanaro P., D'Alessandra Y., Di Stefano V., Melchionna R., Romani S., Pompilio G., et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 2008, 283(23):15878-15883.
232. Hu S., Huang M., Li Z., Jia F., Ghosh Z., Lijkwan M.A., et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 2010, 122(11 Suppl):S124-S131.
233. Crosby M.E., Kulshreshtha R., Ivan M., Glazer P.M. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res 2009, 69(3):1221-1229.
234. Giannakakis A., Sandaltzopoulos R., Greshock J., Liang S., Huang J., Hasegawa K., et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 2008, 7(2):255-264.
235. Kim H.W., Haider H.K., Jiang S., Ashraf M. Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem 2009, 284(48):33161-33168.
236. Chan S.Y., Zhang Y.Y., Hemann C., Mahoney C.E., Zweier J.L., Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab 2009, 10(4):273-284.
237. Semenza G.L. Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem J 2007, 405(1):1-9.
238. Semenza G.L. Hypoxia-inducible factors in physiology and medicine. Cell 2012, 148(3):399-408.
239. Guo L., Qiu Z., Wei L., Yu X., Gao X., Jiang S., et al. The microRNA-328 regulates hypoxic pulmonary hypertension by targeting at insulin growth factor 1 receptor and L-type calcium channel-alpha1C. Hypertension 2012, 59(5):1006-1013.
240. Somlyo A.P., Somlyo A.V. Signal transduction and regulation in smooth muscle. Nature 1994, 372(6503):231-236.
241. Bers D.M. Cardiac excitation-contraction coupling. Nature 2002, 415(6868):198-205.
242. Hofmann F., Flockerzi V., Kahl S., Wegener J.W. L-type CaV1.2 calcium channels: from in vitro findings to in vivo function. Physiol Rev 2014, 94(1):303-326.
243. Liu J.P., Baker J., Perkins A.S., Robertson E.J., Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993, 75(1):59-72.
244. Wu C., So J., Davis-Dusenbery B.N., Qi H.H., Bloch D.B., Shi Y., et al. Hypoxia potentiates microRNA-mediated gene silencing through posttranslational modification of Argonaute2. Mol Cell Biol 2011, 31(23):4760-4774.
245. Bonnet S., Rochefort G., Sutendra G., Archer S.L., Haromy A., Webster L., et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A 2007, 104(27):11418-11423.
246. Jasmin J.F., Mercier I., Dupuis J., Tanowitz H.B., Lisanti M.P. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation 2006, 114(9):912-920.
247. Paulin R., Courboulin A., Meloche J., Mainguy V., Dumas de la Roque E., Saksouk N., et al. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation 2011, 123(11):1205-1215.
248. Lee C., Mitsialis S.A., Aslam M., Vitali S.H., Vergadi E., Konstantinou G., et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 2012, 126(22):2601-2611.
249. Eiring A.M., Harb J.G., Neviani P., Garton C., Oaks J.J., Spizzo R., et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 2010, 140(5):652-665.
250. Meng F., Henson R., Wehbe-Janek H., Smith H., Ueno Y., Patel T. The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem 2007, 282(11):8256-8264.
251. Curtale G., Mirolo M., Renzi T.A., Rossato M., Bazzoni F., Locati M. Negative regulation of Toll-like receptor 4 signaling by IL-10-dependent microRNA-146b. Proc Natl Acad Sci U S A 2013, 110(28):11499-11504.
252. Mycko M.P., Cichalewska M., Machlanska A., Cwiklinska H., Mariasiewicz M., Selmaj K.W. MicroRNA-301a regulation of a T-helper 17 immune response controls autoimmune demyelination. Proc Natl Acad Sci U S A 2012, 109(20):E1248-E1257.
253. Iliopoulos D., Jaeger S.A., Hirsch H.A., Bulyk M.L., Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010, 39(4):493-506.
254. Adams H.P., del Zoppo G., Alberts M.J., Bhatt D.L., Brass L., Furlan A., et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke; J Cereb Circ 2007, 38(5):1655-1711.
255. Cahill J., Calvert J.W., Zhang J.H. Mechanisms of early brain injury after subarachnoid hemorrhage. J Cereb Blood Flow Metab: Off J Int Soc Cereb Blood Flow Metab 2006, 26(11):1341-1353.
256. Bardutzky J., Schwab S. Antiedema therapy in ischemic stroke. Stroke; J Cereb Circ 2007, 38(11):3084-3094.
257. Jeyaseelan K., Lim K.Y., Armugam A. MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion. Stroke; J Cereb Circ 2008, 39(3):959-966.
258. Toung T.J., Traystman R.J., Hurn P.D. Estrogen-mediated neuroprotection after experimental stroke in male rats. Stroke; J Cereb Circ 1998, 29(8):1666-1670.
259. Yang S.H., Shi J., Day A.L., Simpkins J.W. Estradiol exerts neuroprotective effects when administered after ischemic insult. Stroke; J Cereb Circ 2000, 31(3):745-749. discussion 749-750.
260. Hurn P.D., Macrae I.M. Estrogen as a neuroprotectant in stroke. J Cereb blood Flow Metab: Off J Int Soc Cereb Blood Flow Metabolism. 2000, 20(4):631-652.
261. Siegel C., Li J., Liu F., Benashski S.E., McCullough L.D. miR-23a regulation of X-linked inhibitor of apoptosis (XIAP) contributes to sex differences in the response to cerebral ischemia. Proc Natl Acad Sci U S A 2011, 108(28):11662-11667.
262. Frigeri A., Gropper M.A., Turck C.W., Verkman A.S. Immunolocalization of the mercurial-insensitive water channel and glycerol intrinsic protein in epithelial cell plasma membranes. Proc Natl Acad Sci U S A 1995, 92(10):4328-4331.
263. Nielsen S., Nagelhus E.A., Amiry-Moghaddam M., Bourque C., Agre P., Ottersen O.P. Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci: Off J Soc Neurosci 1997, 17(1):171-180.
264. Manley G.T., Fujimura M., Ma T., Noshita N., Filiz F., Bollen A.W., et al. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med 2000, 6(2):159-163.
265. Sepramaniam S., Armugam A., Lim K.Y., Karolina D.S., Swaminathan P., Tan J.R., et al. MicroRNA 320a functions as a novel endogenous modulator of aquaporins 1 and 4 as well as a potential therapeutic target in cerebral ischemia. J Biol Chem 2010, 285(38):29223-29230.
266. Ren X.P., Wu J., Wang X., Sartor M.A., Qian J., Jones K., et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation 2009, 119(17):2357-2366.
267. Quraishe S., Asuni A., Boelens W.C., O'Connor V., Wyttenbach A. Expression of the small heat shock protein family in the mouse CNS: differential anatomical and biochemical compartmentalization. Neuroscience 2008, 153(2):483-491.
268. Bronisz A., Godlewski J., Wallace J.A., Merchant A.S., Nowicki M.O., Mathsyaraja H., et al. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol 2012, 14(2):159-167.
269. Wu Y.Y., Chen Y.L., Jao Y.C., Hsieh I.S., Chang K.C., Hong T.M. miR-320 regulates tumor angiogenesis driven by vascular endothelial cells in oral cancer by silencing neuropilin 1. Angiogenesis 2014, 17(1):247-260.
270. Tang H., Lee M., Sharpe O., Salamone L., Noonan E.J., Hoang C.D., et al. Oxidative stress-responsive microRNA-320 regulates glycolysis in diverse biological systems. FASEB journal. Off Publ Fed Am Soc Exp Biol 2012, 26(11):4710-4721.
271. Kim D.H., Saetrom P., Snove O., Rossi J.J. MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci U S A 2008, 105(42):16230-16235.
272. Lee J.M., Zipfel G.J., Choi D.W. The changing landscape of ischaemic brain injury mechanisms. Nature 1999, 399(6738 Suppl):A7-A14.
273. Edbauer D., Neilson J.R., Foster K.A., Wang C.F., Seeburg D.P., Batterton M.N., et al. Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron 2010, 65(3):373-384.
274. Saba R., Storchel P.H., Aksoy-Aksel A., Kepura F., Lippi G., Plant T.D., et al. Dopamine-regulated microRNA MiR-181a controls GluA2 surface expression in hippocampal neurons. Mol Cell Biol 2012, 32(3):619-632.
275. Harraz M.M., Eacker S.M., Wang X., Dawson T.M., Dawson V.L. MicroRNA-223 is neuroprotective by targeting glutamate receptors. Proc Natl Acad Sci U S A 2012, 109(46):18962-18967.
276. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366(9491):1059-1062.
277. Beltran-Sanchez H., Harhay M.O., Harhay M.M., McElligott S. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010. J Am Coll Cardiol 2013, 62(8):697-703.
278. Ervin R.B. Preval metabolic syndrome among adults 20 years age over, by Sex age, race Ethn body mass index: United States, 2003-2006. Natl Health Stat Rep 2009, (13):1-7.
279. Herder C., Karakas M., Koenig W. Biomarkers for the prediction of type 2 diabetes and cardiovascular disease. Clin Pharmacol Ther 2011, 90(1):52-66.
280. Raitoharju E., Seppala I., Oksala N., Lyytikainen L.P., Raitakari O., Viikari J., et al. Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways underlying metabolic syndrome. Mol Cell Endocrinol 2014, 391(1-2):41-49.
281. Hulsmans M., Sinnaeve P., Van der Schueren B., Mathieu C., Janssens S., Holvoet P. Decreased miR-181a expression in monocytes of obese patients is associated with the occurrence of metabolic syndrome and coronary artery disease. J Clin Endocrinol Metab 2012, 97(7):E1213-E1218.
282. Brummelkamp T.R., Nijman S.M., Dirac A.M., Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003, 424(6950):797-801.
283. Trompouki E., Hatzivassiliou E., Tsichritzis T., Farmer H., Ashworth A., Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFRfamily members. Nature 2003, 424(6950):793-796.
284. Puigserver P., Spiegelman B.M. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003, 24(1):78-90.
285. Rosen E.D., Spiegelman B.M. What we talk about when we talk about fat. Cell 2014, 156(1-2):20-44.
286. Carrer M., Liu N., Grueter C.E., Williams A.H., Frisard M.I., Hulver M.W., et al. Control of mitochondrial metabolism and systemic energy homeostasis by microRNAs 378 and 378. Proc Natl Acad Sci U S A 2012, 109(38):15330-15335.
287. Grueter C.E., van Rooij E., Johnson B.A., Deleon S.M., Sutherland L.B., Qi X., et al. A cardiac MicroRNA governs systemic Energy homeostasis by regulation of MED13. Cell 2012, 149(3):671-683.
288. Spinazzola A., Viscomi C., Fernandez-Vizarra E., Carrara F., D'Adamo P., Calvo S., et al. MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nat Genet 2006, 38(5):570-575.
289. Krick S., Shi S., Ju W., Faul C., Tsai S.Y., Mundel P., et al. Mpv17l protects against mitochondrial oxidative stress and apoptosis by activation of Omi/HtrA2 protease. Proc Natl Acad Sci U S A 2008, 105(37):14106-14111.
290. Zhuang G., Meng C., Guo X., Cheruku P.S., Shi L., Xu H., et al. A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation. Circulation 2012, 125(23):2892-2903.
291. Lee E.K., Lee M.J., Abdelmohsen K., Kim W., Kim M.M., Srikantan S., et al. miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol 2011, 31(4):626-638.
292. Kim C., Lee H., Cho Y.M., Kwon O.J., Kim W., Lee E.K. TNFalpha-induced miR-130 resulted in adipocyte dysfunction during obesity-related inflammation. FEBS Lett 2013, 587(23):3853-3858.
293. Trajkovski M., Hausser J., Soutschek J., Bhat B., Akin A., Zavolan M., et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011, 474(7353):649-653.
294. Poy M.N., Eliasson L., Krutzfeldt J., Kuwajima S., Ma X., Macdonald P.E., et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004, 432(7014):226-230.
295. Sen S., Kundu G., Mekhail N., Castel J., Misono K., Healy B. Myotrophin: purification of a novel peptide from spontaneously hypertensive rat heart that influences myocardial growth. J Biol Chem 1990, 265(27):16635-16643.
296. Sarkar S., Leaman D.W., Gupta S., Sil P., Young D., Morehead A., et al. Cardiac overexpression of myotrophin triggers myocardial hypertrophy and heart failure in transgenic mice. J Biol Chem 2004, 279(19):20422-20434.
297. Antonin W., Riedel D., von Mollard G.F. The SNARE Vti1a-beta is localized to small synaptic vesicles and participates in a novel SNARE complex. J Neurosci: Off J Soc Neurosci 2000, 20(15):5724-5732.
298. Poy M.N., Hausser J., Trajkovski M., Braun M., Collins S., Rorsman P., et al. miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci U S A 2009, 106(14):5813-5818.
299. Xu G., Chen J., Jing G., Shalev A. Thioredoxin-interacting protein regulates insulin transcription through microRNA-204. Nat Med 2013, 19(9):1141-1146.
300. Shao S., Fang Z., Yu X., Zhang M. Transcription factors involved in glucose-stimulated insulin secretion of pancreatic beta cells. Biochem Biophys Res Commun 2009, 384(4):401-404.
301. Ruan Q., Wang T., Kameswaran V., Wei Q., Johnson D.S., Matschinsky F., et al. The microRNA-21-PDCD4 axis prevents type 1 diabetes by blocking pancreatic beta cell death. Proc Natl Acad Sci U S A 2011, 108(29):12030-12035.
302. Jordan S.D., Kruger M., Willmes D.M., Redemann N., Wunderlich F.T., Bronneke H.S., et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat Cell Biol 2011, 13(4):434-446.
303. Vetere A., Choudhary A., Burns S.M., Wagner B.K. Targeting the pancreatic beta-cell to treat diabetes. Nat Rev Drug Discov 2014, 13(4):278-289.
304. Bouwens L., Houbracken I., Mfopou J.K. The use of stem cells for pancreatic regeneration in diabetes mellitus. Nat Rev Endocrinol 2013, 9(10):[598]-606.